Pluripotent stem cell (PSC) research is an expanding field that has the potential to change the way human diseases are studied and treated. See More The ability to differentiate embryonic stem (ES) cells and induced pluripotent stem (iPS) cells to specific downstream cell types opens up new avenues for drug development and regenerative medicine. From generation of iPS cells to maintenance, differentiation, characterization, and cryopreservation of ES and iPS cells, see how you can "Maximize Your Pluripotential" with the most complete, defined system for ES and iPS cell culture. For help with your hPSC workflow decision making, use our infographics to find the right reagents for you.
Read this mini-review to learn more about Pluripotent Stem Cells.See Less
Explore These Resources
Aryl Hydrocarbon Receptor Inhibition Promotes Hemato-Lymphoid Development from Human Pluripotent Stem Cells
To model hematopoiesis, human embryonic stem cells (hESCs) were allowed to differentiate in defined conditions in the presence of the aryl hydrocarbon receptor (AHR) antagonist stemreginin-1 (SR-1) or AHR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin. The authors demonstrated a significant increase in CD34+CD31+ hemato-endothelial cells in SR-1 treated hESCs, as well as a two-fold expansion of CD34+CD45+ hematopoietic progenitor cells.ESC & iPSC News Volume 12.20, May 24, 2017. Read full issue at